A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Table 2 Median change of the Ki-67 labeling index and progesterone receptors

Variable	Arm	Baseline	Surgery
		Median IQR	Median IQR	Median change	Contrast P
Ki-67	P	16 (9 to 22)	15 (10 to 23)	0 (-4 to 3)	T vs. R P = 0.76
	T	18 (14 to 28)	19.5 (12.5 to 26.5)	0 (-5 to 4)	T + R vs. P P = 0.78
	R	21.5 (15 to 27)	21 (15 to 25)	0 (-5 to 4)
PgR	P	80 (65 to 95)	90 (60 to 95)	0 (0 to10)	T vs. R P = 0.10
	T	65 (10 to 90)	65 (22.5 to 92.5)	4.5 (-0.5 to 12.5)	T + R vs. P P = 0.26
	R	80 (45 to 90)	70 (20 to 90)	0 (-5 to 5)
ER	P	90 (80 to 95)	90 (80 to 95)	0 (0 to 1)	T vs. R P = 0.99
	T	90 (80 to 90)	90 (80 to 95)	1 (0 to 5)	T + R vs. P P = 0.82
	R	90 (90 to 95)	90 (85 to 95)	0 (0 to 1)

IQR, interquartile range; P, placebo; T, tamoxifen 10 mg/week; R, raloxifene 60 mg/day; PgR, progesterone receptor; ER, estrogen receptor.

ISSN: 1465-542X